NASDAQHealth CareHealth Information ServicesSnapshot 2026-07-23
Reading SDGR? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is in a transition phase, focusing on hosted software licensing and increasing drug discovery revenue, but is currently loss-making with elevated risks.
The market appears to have priced in a durable premium compared to peers, reflecting a justified valuation despite the company's losses. There is a notable expectations gap, indicating that investors may not fully believe in the company's growth potential.
Management's execution on priorities shows mixed results, with drug discovery revenue growing but software revenue declining. The near-term risk is elevated due to a history of earnings misses, but the probability of a miss is relatively low at this time.
The thesis hinges on the performance of sector bellwethers like VEEV, BTSG, and TEM, which could influence SDGR's growth trajectory. Additionally, any cuts to guidance in future calls would negatively impact sentiment.
In the next 1 to 3 years, SDGR's performance will depend on its ability to navigate sector dynamics and execute on its strategic priorities. Not investment advice.
The most important moves since the prior daily snapshot.
Company momentum rose by 14.4 points (from -14.6 to -0.2).
Yes, our read has weakened. This change is primarily driven by the latest earnings miss, which raises concerns about the company's performance. The management's commitment appears to be lagging, contributing to a more cautious outlook.
as of 2026-07-23
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: A drop below this number would show ongoing challenges in revenue growth. This could signal deeper issues in the business model.
Confirms:Q2 revenue was below $58.6M. This shows revenue is still going down.
Disproves:Q2 revenue is stable or above $58.6M. This means recovery efforts are working.
Why it matters: If it drops below this level, it shows problems with moving to hosted software.
Confirms:Q2 ACV reported at less than $19 million, indicating weaker demand.
Disproves:Q2 ACV was over $23 million. This shows strong customer interest.
Why it matters: The result of this lawsuit could change how the company operates. Legal issues can hurt stock prices.
Confirms:Updates on the lawsuit show a resolution that is good for the company.
Disproves:Negative news in the lawsuit hurts the company's position.
Why it matters: Positive data could increase confidence in Schrödinger's drug pipeline. It may attract more investor interest.
Confirms:Positive early data was shared for SGR-3515 at a big conference.
Disproves:Negative data or no data was shared for SGR-3515. This raises concerns about the drug's success.
Why it matters: Partnerships can help speed up the development and sale of these important drugs.
Confirms:Announcement of a strategic partnership for SGR-1505 or SGR-3515 within six months.
Disproves:No partnerships announced. This could cause delays in development.
Why it matters: If they exceed this target, it shows strong demand for Schrödinger's services. It also supports their growth plan.
Confirms:Drug discovery revenue was over $65 million in 2026.
Disproves:Drug discovery revenue dropped below $55 million. This may show problems in partnerships.
Why it matters: Improving operating income is crucial for the company's financial health. A smaller loss would show progress.
Confirms:Operating income was less than -$48.8M. This shows some improvement.
Disproves:Operating income worsened to more than -$48.8M. This shows problems in cost management.
Why it matters: A drop in cash flow could signal operational issues. Strong cash flow is key for growth.
Confirms:Cash flow from operations was below $144.1M. This may mean there are problems.
Disproves:Cash flow from operations is above $144.1M. This confirms ongoing operational strength.
Why it matters: The launch could enhance productivity and expand the user base, supporting growth.
Confirms:They announced a successful launch of Bunsen. Users gave positive feedback.
Disproves:Delay in the launch or negative feedback from early users.
Why it matters: Exceeding this threshold would confirm strong growth in drug discovery efforts.
Confirms:Q2 drug discovery revenue was over $25 million. This shows strong results.
Disproves:Q2 drug discovery revenue was under $20 million. This shows possible problems.
